Your session is about to expire
← Back to Search
Glutaminase Inhibitor CB-839 for Myelodysplastic Syndrome
Study Summary
This trial is testing a new combination of drugs to treat myelodysplastic syndrome, to see if it is more effective than the current standard of care, and to assess side effects.
- Myelodysplastic Syndrome
- Aplastic Anemia
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 trial • 48 Patients • NCT02038777Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is Glutaminase Inhibitor CB-839 a new medication?
"There are 185 clinical trials investigating Glutaminase Inhibitor CB-839 with 33 of those in Phase 3. Most of these clinical trials for Glutaminase Inhibitor CB-839 are based in Saint Louis, Missouri; however, there are 5786 locations running clinical trials for Glutaminase Inhibitor CB-839 globally."
For what purpose is Glutaminase Inhibitor CB-839 most commonly prescribed?
"Glutaminase Inhibitor CB-839 has shown to be an effective treatment for patients with malignant neoplasms, 20-30% blasts, and neutropenia and/or thrombocytopenia."
Is it still possible to sign up for this experiment?
"Unfortunately, this specific trial is not searching for any more patients at the moment. Although, it's good to know that there are over 3000 other trials currently underway that might be a better fit."
What is the total sample size for this research project?
"This study has already completed patient recruitment. The trial was advertised from November 15th, 2017 to September 22nd, 2022. However, there are still other medical trials open for patients suffering from myelodysplastic syndromes and Glutaminase Inhibitor CB-839."
Share this study with friends
Copy Link
Messenger